-
Review your patient charts for the past month. If national statistics are any indication, chances are many of those cases include a diagnosis of urinary tract infection (UTI).
-
Ask the next patient who comes in your office, "What is the most effective reversible contraceptive?" How many of them will name the intrauterine device (IUD)?
-
Results from a follow-up study of women who were enrolled in the Women's Health Initiative (WHI) indicate that while many health effects of hormones are diminished after about three years after cessation of combined hormone therapy (CHT), risks for stroke, blood clots, and cancer remain elevated.
-
Early research indicates that beneficial bacteria found in the healthy vagina aids in reducing the amount of vaginal HIV among HIV-infected women and may make it more difficult for the virus to spread.
-
Are you talking to your patients about pelvic floor disorders (PFDs)? You should. Results from a study of 4,000 U.S. women ages 25-84 indicate one-third of them reported one or more pelvic floor disorders.
-
In 1998, the United States was on the verge of eliminating syphilis, one of the most prevalent sexually transmitted diseases (STDs). Today, the national syphilis rate has increased for the seventh consecutive year, according to preliminary data presented at the March 2008 National STD Prevention Conference.
-
Several strides have been made when it comes to cervical cancer prevention. Research has identified high-risk human papillomaviruses (HPVs) as causal agents, a test has been developed to detect HPV infection (Digene HPV Test, Digene Corp.; Gaithersburg, MD), and a vaccine (Gardasil, Merck & Co.; Whitehouse Station, NJ) is now marketed to prevent infection of the most common types of HPV.
-
An experimental anti-HIV tenofovir gel is safe for women to use on a daily basis, according to research conducted by the scientists at the University of Pittsburgh (PA) School of Medicine and the University of Alabama at Birmingham (UAB).
-
Bad news: Results of the first large-scale effectiveness trial for a microbicide indicate that while the candidate, Carraguard, is safe, it was not shown to be effective in preventing male-to-female transmission of HIV.
-
Be sure to pencil in dates for two upcoming women's health conferences sponsored by the Association of Reproductive Health Professionals, Planned Parenthood Federation, the Society of Family Planning, and the National Association of Nurse Practitioners in Women's Health (NPWH).